Compare GLDD & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GLDD | ANNX |
|---|---|---|
| Founded | 1890 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 972.5M |
| IPO Year | 2007 | 2020 |
| Metric | GLDD | ANNX |
|---|---|---|
| Price | $17.01 | $5.25 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $17.00 | $16.50 |
| AVG Volume (30 Days) | ★ 2.5M | 1.9M |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 28.57 | N/A |
| EPS | ★ 1.08 | N/A |
| Revenue | ★ $702,503,000.00 | N/A |
| Revenue This Year | $5.19 | N/A |
| Revenue Next Year | $7.56 | $16,320.74 |
| P/E Ratio | $15.74 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $10.37 | $1.85 |
| 52 Week High | $17.02 | $7.18 |
| Indicator | GLDD | ANNX |
|---|---|---|
| Relative Strength Index (RSI) | 68.41 | 35.85 |
| Support Level | $14.60 | $4.79 |
| Resistance Level | N/A | $5.61 |
| Average True Range (ATR) | 0.03 | 0.28 |
| MACD | -0.06 | -0.08 |
| Stochastic Oscillator | 80.00 | 13.33 |
Great Lakes Dredge & Dock Corp is a provider of dredging services in the United States. The Company is also fully engaged in expanding its core business into the offshore energy industry. Dredging involves the enhancement or preservation of the navigability of waterways or the protection of shorelines through the removal or replenishment of soil, sand, or rock. Company work generally is to performed in coastal waterways and deep water ports. Its project portfolio includes Coastal Restoration, Coastal Protection, Ports and Harbors, International, and Inland Dredging.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.